AN2 Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Epetraborole is advancing to Phase 2 for polycythemia vera, with dosing set for August and initial data expected in Q4. The oral agent aims to provide stable hematocrit control and may offer disease-modifying potential. Additional pipeline programs include trials for M. abscessus and Chagas disease.
-
Epetraborole is being advanced into phase II trials for PV, targeting a major unmet need for oral, red cell-specific therapies. The drug has shown consistent hematocrit control with minimal side effects and could offer rapid, durable benefits for patients inadequately managed by current treatments.
Fiscal Year 2025
-
A major strategic pivot followed a phase III readout in NTM lung disease, with expanded focus on oncology and infectious diseases. Lead oncology and Chagas programs show strong preclinical and early clinical data, with multiple milestones expected in 2026.
-
The pipeline features novel boron-based drugs for infectious diseases and oncology, with strong preclinical and early clinical results in Chagas disease and melioidosis, and a strategic pivot in NTM to target abscessus. Oncology programs target ENPP1 and PI3Kα with best-in-class ambitions.
-
Epetraborole is advancing for severe, refractory NTM lung disease, with phase III data expected in Q2. The primary endpoint is now QOL-B respiratory demand, aligning with FDA guidance, and the drug has shown clinical benefit and good tolerability. The pipeline includes Chagas disease and oncology programs, with cash runway through 2027.
-
The company leverages boron chemistry for a diverse pipeline in infectious diseases and oncology, with key milestones ahead including phase III data for NTM lung disease and phase II starts for Chagas and melioidosis. Cash runway extends through 2027, supporting ongoing development.
-
The company highlighted progress in its boron chemistry platform, with positive Phase II results for epetraborole in NTM lung disease and a robust pipeline including Chagas and melioidosis programs. Regulatory engagement and new clinical data are expected soon.